Elisabeth I Minder

Summary

Publications

  1. doi request reprint Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders
    Elisabeth I Minder
    Stadtspital Triemli, Porphyria Outpatient Clinics, Zurich, Switzerland
    Clin Pharmacokinet . 2017
  2. pmc Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal
    Elisabeth I Minder
    Stadtspital Triemli, Zentrallabor, Birmensdorferstrasse 497, CH 8063 Zurich, Switzerland
    Health Qual Life Outcomes 8:60. 2010
  3. pmc Effects of different centrifugation conditions on clinical chemistry and Immunology test results
    Elisabeth I Minder
    Stadtspital Triemli, Central laboratory Birmensdorferstrasse 497 CH 8063 Zürich Switzerland
    BMC Clin Pathol 11:6. 2011
  4. doi request reprint In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability
    Jasmin Barman-Aksözen
    Institute of Laboratory Medicine, Triemli Hospital, Zurich, Switzerland
    Blood Cells Mol Dis 54:71-7. 2015
  5. doi request reprint Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone
    Juergen H Harms
    Stadtspital Triemli, Central Laboratory, University Hospital of Zurich, Zurich, Switzerland
    Photochem Photobiol 85:1434-9. 2009
  6. doi request reprint Exacerbation of erythropoietic protoporphyria by hyperthyroidism
    Elisabeth I Minder
    Central Laboratory, Triemli Hospital, Zurich, Switzerland
    J Inherit Metab Dis 33:S465-9. 2010
  7. doi request reprint Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias
    Xiaoye Schneider-Yin
    Institute of Laboratory Medicine and Swiss Porphyrin Reference Laboratory, Stadtspital Triemli, Zurich, Switzerland
    J Hepatol 62:734-8. 2015
  8. doi request reprint Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria
    Elisabeth I Minder
    Institute of Laboratory Medicine, Stadtspital Triemli, CH 8063 Zurich, Switzerland
    Expert Rev Clin Pharmacol 8:43-53. 2015
  9. doi request reprint Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-oxoglutarate dependent dioxygenase Jmjd6 and U2AF(65.)
    Jasmin Barman-Aksözen
    Institute of Laboratory Medicine, Stadtspital Triemli, Zurich, Switzerland
    Blood Cells Mol Dis 51:151-61. 2013

Collaborators

  • Peter Bauer
  • Jasmin Barman-Aksözen
  • Xiaoye Schneider-Yin
  • Juergen H Harms
  • Axel zur Hausen
  • Michel van Geel
  • Pamela Poblete-Gutiérrez
  • Reno S Bladergroen
  • Véronique J Winnepenninckx
  • Philip Went
  • Roy H E Cloots
  • Paul Komminoth
  • Gianfranco Biolcati
  • Marko Siegesmund
  • CHRISTOPHER SCHROEDER
  • Anne Moon van Tuyll van Serooskerken
  • Jorge Frank
  • Ann Driessen
  • Markus Weber
  • Carina Schubiger
  • Afzal M Dogar
  • Chantal Béguin
  • Christoph E Minder
  • Stephan Lautenschlager

Detail Information

Publications9

  1. doi request reprint Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders
    Elisabeth I Minder
    Stadtspital Triemli, Porphyria Outpatient Clinics, Zurich, Switzerland
    Clin Pharmacokinet . 2017
    ..Generally, adverse effects were benign in all trials...
  2. pmc Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal
    Elisabeth I Minder
    Stadtspital Triemli, Zentrallabor, Birmensdorferstrasse 497, CH 8063 Zurich, Switzerland
    Health Qual Life Outcomes 8:60. 2010
    ..No standardized tools to quantify the degree of PP-related phototoxicity and its change by medical intervention have been published...
  3. pmc Effects of different centrifugation conditions on clinical chemistry and Immunology test results
    Elisabeth I Minder
    Stadtspital Triemli, Central laboratory Birmensdorferstrasse 497 CH 8063 Zürich Switzerland
    BMC Clin Pathol 11:6. 2011
    ..WHO guideline proposed a 15 min centrifugation time without citing any scientific publications. The centrifugation time has a considerable impact on the turn-around-time...
  4. doi request reprint In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability
    Jasmin Barman-Aksözen
    Institute of Laboratory Medicine, Triemli Hospital, Zurich, Switzerland
    Blood Cells Mol Dis 54:71-7. 2015
    ..Furthermore, we hypothesize that EPP patients may benefit from a mild iron deficiency since it would limit PPIX production by restricting ALAS2 over-expression...
  5. doi request reprint Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone
    Juergen H Harms
    Stadtspital Triemli, Central Laboratory, University Hospital of Zurich, Zurich, Switzerland
    Photochem Photobiol 85:1434-9. 2009
    ..The findings demonstrate beneficial effects of afamelanotide in patients with EPP. Due to the limited number of patients enrolled and the design being an open-label study, confirmation by a large-scale trial is required...
  6. doi request reprint Exacerbation of erythropoietic protoporphyria by hyperthyroidism
    Elisabeth I Minder
    Central Laboratory, Triemli Hospital, Zurich, Switzerland
    J Inherit Metab Dis 33:S465-9. 2010
    ..Although the exact mechanism whereby Graves' disease interacts with EPP is yet to be explored, we recommend testing thyroid function in EPP patients with liver complication to exclude hyperthyroidism as a potential cause...
  7. doi request reprint Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias
    Xiaoye Schneider-Yin
    Institute of Laboratory Medicine and Swiss Porphyrin Reference Laboratory, Stadtspital Triemli, Zurich, Switzerland
    J Hepatol 62:734-8. 2015
    ..Both PPOX and HMBS, which might act as tumor suppressors, play a crucial role in the development of HCC in these individuals. ..
  8. doi request reprint Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria
    Elisabeth I Minder
    Institute of Laboratory Medicine, Stadtspital Triemli, CH 8063 Zurich, Switzerland
    Expert Rev Clin Pharmacol 8:43-53. 2015
    ..Moreover, we hope that dosage forms suitable for children will be developed in future, as children and adolescents suffer most in protoporphyria. ..
  9. doi request reprint Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-oxoglutarate dependent dioxygenase Jmjd6 and U2AF(65.)
    Jasmin Barman-Aksözen
    Institute of Laboratory Medicine, Stadtspital Triemli, Zurich, Switzerland
    Blood Cells Mol Dis 51:151-61. 2013
    ..This in turn, influences the relative amounts of correct and aberrant FECH mRNA splice products and thus, regulates the FECH enzyme activity. ..